1
|
Bozsó Z, Lapat V, Ott PG, Móricz ÁM. Disparate Effects of Two Clerodane Diterpenes of Giant Goldenrod ( Solidago gigantea Ait.) on Bacillus spizizenii. Int J Mol Sci 2024; 25:1531. [PMID: 38338810 PMCID: PMC10855248 DOI: 10.3390/ijms25031531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 01/21/2024] [Accepted: 01/22/2024] [Indexed: 02/12/2024] Open
Abstract
New substances with antimicrobial properties are needed to successfully treat emerging human, animal, or plant pathogens. Seven clerodane diterpenes, previously isolated from giant goldenrod (Solidago gigantea) root, were tested against Gram-positive Bacillus subtilis, Bacillus spizizenii and Rhodococcus fascians by measuring minimal bactericidal concentration (MBC), minimal inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC50). Two of them, Sg3a (a dialdehyde) and Sg6 (solidagoic acid B), were proved to be the most effective and were selected for further study. Bacillus spizizenii was incubated with the two diterpenes for shorter (1 h) or longer (5 h) periods and then subjected to genome-wide transcriptional analyses. Only a limited number of common genes (28 genes) were differentially regulated after each treatment, and these were mainly related to the restoration of cell membrane integrity and to membrane-related transports. Changes in gene activity indicated that, among other things, K+ and Na+ homeostasis, pH and membrane electron transport processes may have been affected. Activated export systems can be involved in the removal of harmful molecules from the bacterial cells. Inhibition of bacterial chemotaxis and flagellar assembly, as well as activation of genes for the biosynthesis of secondary metabolites, were observed as a general response. Depending on the diterpenes and the duration of the treatments, down-regulation of the protein synthesis-related, oxidative phosphorylation, signal transduction and transcription factor genes was found. In other cases, up-regulation of the genes of oxidation-reduction processes, sporulation and cell wall modification could be detected. Comparison of the effect of diterpenes with the changes induced by different environmental and nutritional conditions revealed several overlapping processes with stress responses. For example, the Sg6 treatment seems to have caused a starvation-like condition. In summary, there were both common and diterpene-specific changes in the transcriptome, and these changes were also dependent on the length of treatments. The results also indicated that Sg6 exerted its effect more slowly than Sg3a, but ultimately its effect was greater.
Collapse
Affiliation(s)
| | | | | | - Ágnes M. Móricz
- Plant Protection Institute, HUN-REN Centre for Agricultural Research, Herman Ottó Str. 15, H-1022 Budapest, Hungary; (Z.B.); (P.G.O.)
| |
Collapse
|
2
|
Yang P, Zhao Y, Liang H, Zhou G, Youssef B, Elhalawani H, Li M, Tan F, Jin Y, Jin H, Zhu H, Mohamed ASR, Chonnipa N, Kannarunimit D, Shi Y, Wang H, Fuller CD. Neutrophil-to-lymphocyte ratio trend: A novel prognostic predictor in patients with nasopharyngeal carcinoma receiving radiotherapy. Int J Biol Markers 2022; 37:270-279. [PMID: 35775111 DOI: 10.1177/03936155221110250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Peripheral neutrophil-lymphocyte ratio (NLR), reflecting immune-inflammation status, shows great potential for tumor progression and outcome. Pre-treatment NLR does not fully reflect the immune-inflammatory response to treatment. This study aimed to introduce the NLR trend as a new indicator and to investigate its prognostic value in patients with nasopharyngeal carcinoma receiving radiotherapy. METHODS This retrospective study evaluated patients with nasopharyngeal carcinoma treated with radiotherapy. The NLR trend value was calculated from the fitted line gradient via the NLRs before, during (at least once), and after each patient's first radiotherapy. The Kaplan-Meier curve and log-rank test were used to calculate and compare survival outcomes of different pretreatment NLRs and NLR trends for progression-free survival, locoregional recurrence-free survival (LRFS), and overall survival at 3 and 5 years. Multivariate Cox regression analyses were performed to assess the association between the NLR trend plus 3- and 5-year overall survival. RESULTS The study included 528 patients. A lower NLR trend predicted worse progression-free survival, LRFS, plus 3- and 5-year overall survival. Multivariate Cox regression analysis showed that the NLR trend independently predicted 3- and 5-year overall survival. Sub-group analysis showed that the prognosis of patients with a low pretreatment NLR and a high NLR trend were superior to those of other groups. CONCLUSION The NLR trend independently predicted the prognosis of patients with nasopharyngeal carcinoma receiving radiotherapy. The NLR trend and the pretreatment NLR combination is more precise than pretreatment NLR in predicting prognosis. A high NLR trend may be evidence of a positive immune response to radiotherapy in patients with nasopharyngeal carcinoma.
Collapse
Affiliation(s)
- Pei Yang
- Xiangya Hospital, 506618Central South University, Changsha, Hunan, People's Republic of China.,Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Yu Zhao
- Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China.,The Miriam Hospital, Providence, RI, USA
| | - Hao Liang
- Institute of TCM Diagnostics, 118393Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China
| | - Guanzhi Zhou
- Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China.,University of South China, Hengyang, Hunan, People's Republic of China
| | - Bassem Youssef
- Department of Radiation Oncology, 11238American University of Beirut, Beirut, Lebanon, Lebanon
| | - Hesham Elhalawani
- Department of Radiation Oncology, 2569Cleveland Clinic, Cleveland, OH, USA
| | - Meizhen Li
- Research Institute of Drug Metabolism and Pharmacokinetics, 159374Xiangya School of Pharmaceutical Sciences, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Fengbo Tan
- Xiangya Hospital, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Yi Jin
- Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Hekun Jin
- Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Hong Zhu
- Xiangya Hospital, 506618Central South University, Changsha, Hunan, People's Republic of China
| | | | - Nantavithya Chonnipa
- Department of Medicine, 26683Chulalongkorn University/King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| | - Danita Kannarunimit
- Department of Medicine, 26683Chulalongkorn University/King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| | - Yingrui Shi
- Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Hui Wang
- Key Laboratory of Translational Radiation Oncology, 117924Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, 506618Central South University, Changsha, Hunan, People's Republic of China
| | - Clifton David Fuller
- Department of Radiation Oncology, 4002MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|